Across
- 4. A condition characterized by serum glucose > 600mg/dl, elevated serum osmolality, and urine negative for ketones
- 7. Condition associated with symptoms of tachycardia, diaphoresis, tremors, and mental confusion
- 11. Is first line therapy for patients with Type 1 diabetes
- 12. Relative contraindication/precaution for use of DPP4 inhibitors and GLP-1 agonists
- 13. causes glucose dependent insulin secretion
- 14. Classification for patients with HbA1c between 5.7% and 6.4%
- 16. A medication that should be used with caution in patients with Osteoporosis
- 17. One of the three predominant symptoms of hyperglycemia
- 18. Generic name for a basal insulin
- 20. A GLP-1 agonist that does not have a lead-in dose
- 21. Known to have active metabolites
- 22. decreases hepatic glucose production
- 23. Must be administered with first bite of carbohydrate containing meal
Down
- 1. The only SGLT-2 inhibitor thus far not showing robust benefit for patients with CKD, HF, or reduction in MACE outcomes
- 2. A medication class with a U.S. box warning for heart failure NYHA Class III-IV
- 3. Electrolyte disorder that may be associated with SGLT-2 inhibitor therapy
- 5. Absolute contraindication for use of GLP-1 agonist (two words, no spaces)
- 6. The only DPP-4 inhibitor that does not require a renal dose adjustment
- 8. Generic name for a rapid acting insulin
- 9. A central neuropathy that effects gastric emptying
- 10. Causes glucose independent insulin secretion
- 15. The only GLP-1 agonist that is available in an oral formulation
- 19. Classification for patients with a HbA1c >6.5%